24 articles
ingredient-context
A six-day combo of two old generic drugs, vitamin D analog calcipotriene and chemo agent 5-fluorouracil, cut skin cancer recurrence fourfold in a 3-year study, and is now being tested in transplant patients.
source-note
Lisraya is the first oral therapy approved for dermatomyositis, not the first drug overall, and its pivotal trial only compared the drug to placebo, not to existing options.
source-note
A new JID paper claims fibroblast collapse drives skin aging "in vivo," but the underlying mechanism was first proposed in 2008 and tested mostly in culture and mice until now.
ingredient-context
A conference Q&A urging dermatology clinicians to embrace immunologic pathways and push harder for pediatric biologics glosses over how narrow FDA-approved options for children actually are, and how much the message doubles as promotion for the sponsoring conference.
ingredient-context
Conexeu Sciences is betting that rebuilding skin's collagen scaffold, not just adding volume, is the next frontier in aesthetics — and that GLP-1 drugs just created the patient population to prove it.
source-note
A JAAD comment challenges a Mayo Clinic cohort study that found isotretinoin doesn't shorten teens' final height, pointing instead to the slowed growth velocity the study measured along the way.
Article
Clear Health markets Isoclear as the first prescription topical isotretinoin system available in the United States, but its own product page discloses that the clinical evidence behind it comes from the ingredient generally, including products once sold abroad, not from trials of this specific formulation.
Article
The Journal of Investigative Dermatology's August 2026 issue carries a two-page Letters to the Editor essay, not a study, in which two dermatologists and an artist read Xu Beihong's 1930s ink painting Eight Horses as an argument for training clinicians to look closely; it cites no data for that claim.
Article
A new preclinical study of a Psorospermum febrifugum bark-extract cream reports lipase inhibition, sebum reduction, and dermal safety in rats, but never tests the finished cream against Cutibacterium acnes, the bacterium the condition is named for.
Article
A new ex vivo study finds that FLCN, the gene mutated in Birt-Hogg-Dube syndrome, suppresses hair follicle growth in organ-cultured human follicles, but the syndrome it causes in real skin builds disorganized follicular growths, not fuller hair.
Article
An August review suggests UPF labeling for adhesive sun patches, but current AATCC and ASTM standards address textile fabrics and products. The supporting SPF 100 result came from instrument testing of an experimental material, leaving retail patches without a clean comparison to sunscreen or clothing labels.
Article
A new JAMA Dermatology viewpoint argues most isotretinoin patients don't need routine liver and lipid testing, but the drug's FDA-approved label never actually specified the monthly schedule that became dermatology's default. That habit was built by clinical culture over three decades, not by regulation, and it is the fourth step in a ten-year sequence of evidence pulling practice back toward what the label always allowed.
Article
ITA calculates a color angle from lightness and yellowness. Converting its six categories into Fitzpatrick types adds a claim about sun reactivity that a photograph does not contain, even before lighting error is considered.
Article
Itching with no visible rash has a documented but narrow link to cancer, strongest in Hodgkin lymphoma, where it can appear years before diagnosis yet doesn't track with tumor size. The biology behind it is still unresolved, and most unexplained itch traces back to something else entirely.
Article
No trial has ever tested the new oral psoriasis drug icotrokinra against injectable IL-23 inhibitors head to head, and the indirect comparisons published so far, including two tied to the drugmakers involved, disagree with each other.
Article
A new light-scattering method for catching early emulsion breakdown, built to spot phase separation and freeze damage before they're visible, comes from the quality-control lab of one of the world's largest cosmetics contract manufacturers, whose factories make face masks and skincare sold under hundreds of other companies' names.
Article
A new review of antimicrobial peptides in skin cancer names LTX-315 as a clinical candidate, but the compound is a synthetic redesign of a cow's-milk peptide, not a skin peptide, and it had already been renamed ruxotemitide and moved through two Phase II melanoma trials by the time the review reached print.
Article
A 40-patient Phase 2 trial of the topical gel TolaSure for epidermolysis bullosa simplex is nearing an interim data check, but the predecessor study its confidence rests on enrolled six adults instead of the ten planned and still has no results posted on ClinicalTrials.gov more than three years after it ended.
Article
A short communication published August 10 in the Journal of Investigative Dermatology reports a generative method for narrowing Fitzpatrick skin-tone disparities in AI skin-tumor classification; PubMed's affiliation records show the nine-person team spans hospitals in Seoul, the Philippines, and Ethiopia, a detail the paper's public summary leaves out.
Article
The paper finds a recurring gene-expression signature across archived atopic dermatitis datasets. It does not establish a clinical diagnostic test: metabolism and immune cells were inferred from transcriptomic data, and no prospective diagnostic cohort or locked assay was evaluated.
Article
A new retrospective study on predictors of systemic treatment response in pediatric alopecia areata went online this month with no public abstract yet, but the treatment landscape it examines is checkable now: only one systemic drug is FDA-approved for children with the condition, and only for ages twelve and up.
Article
A July 2026 expert advisory calls CTMP a cornerstone of sensitive-skin care; CTMP is a Galderma trademark, and Galderma funded the meeting and manuscript. Its disclosures also list two company employees as authors and personal fees from Galderma for the other authors.
Article
A formal exchange in a major dermatology journal shows specialists still disagree about routinely testing for gut inflammation before starting bimekizumab for hidradenitis suppurativa, and the reply's byline mixes independent academics with employees of the drug's manufacturer.
Article
A search of the public archive of U.S. appellate opinions turns up only two published cases that ever use the clinical term delusional parasitosis, and in neither one is the diagnosis itself what the court had to decide.